A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Condition:   Chronic Thromboembolic Pulmonary Hypertension Interventions:   Drug: Macitentan;   Drug: Placebo Sponsor:   Actelion Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Campean IA, Lang IM Abstract Introduction: Despite an increasingly older pulmonary hypertension (PH) population, data on PH treatments in these patients are limited because there exist no clinical studies dedicated to geriatric groups. Furthermore, elderly patients with comorbidities have been systematically excluded from clinical trials, limiting the evidence base for drugs approved for pulmonary arterial hypertension (PAH).Areas covered: This review is focused on the diagnosis and treatment of pulmonary hypertension (PH) in the elderly, which is a hot topic today. Areas covered by the authors include cur...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
SOUTH SAN FRANCISCO, CA, April 3, 2020 – Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson &Johnson, today announced that CHEST, the official publication of the American College of Chest Physicians, published results from an expert Delphi consensus survey that help provide additional insights for physicians to advance the care of patients with pulmonary arterial hypertension (PAH).The Prostacyclin International Expert Panel developed the consensus opinions based on common clinical scenarios in which they considered adding oral prostacyclin pathway agents (PPAs), including UPTRAVI®...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
The recently updated European Society of Cardiology/European Respiratory Society guidelines for acute pulmonary embolism (PE) underline the importance of appropriate long-term management of PE sequelae in the era of extended anticoagulation [1]. Chronic thromboembolic disease (CTED) is one of several conditions contributing to breathlessness in this setting, i.e. persistent pulmonary vascular obstruction on imaging, with no evidence of pulmonary hypertension at rest. CTED is increasingly encountered in pulmonary vascular disease clinics following acute PE, and its diagnosis relies heavily on careful exclusion of other cond...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Correspondence Source Type: research
Beyond the major gene BMPR2, several new genes predisposing to PAH have been identified during the last decade. Recently, preliminary evidence of the involvement of the KDR gene was found in a large genetic association study. We prospectively analysed the KDR gene by targeted panel sequencing in a series of 311 PAH patients referred to a clinical molecular laboratory for genetic diagnosis of PAH. Two index cases with severe PAH from two different families were found to carry a loss-of-function mutation in the KDR gene. These two index cases were clinically characterised by low diffusing capacity for carbon monoxide adjuste...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Mechanisms of lung disease, Pulmonary vascular disease Original Articles: Pulmonary hypertension and basic science Source Type: research
The comment by C. McCabe and colleagues provides thoughtful insights into the late sequalae of pulmonary embolism. The authors' views and suggestions, based on their clinical experience and expertise, may prove helpful in the ongoing process of reliably (and meaningfully) distinguishing chronic thromboembolic pulmonary hypertension (CTEPH) from chronic thromboembolic disease (CTED) without pulmonary hypertension at rest.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Correspondence Source Type: research
Authors: Sugimoto K, Yoshihisa A, Nakazato K, Yokokawa T, Misaka T, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Ishida T, Takeishi Y Abstract Pulmonary hypertension (PH) caused by left-sided heart disease (LHD-PH) is classified into 2 types: isolated post-capillary PH (Ipc-PH) and combined pre- and post-capillary PH (Cpc-PH). However, the impact of pulmonary vascular resistance (PVR) or diastolic pressure gradient (DPG) on the prognosis of LHD-PH has varied among previous studies. Thus, we verified the significance of PVR or DPG on the prognosis of LHD-PH in our series.We analyzed 243 consecutive LHD-PH patients. The...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Condition:   Pulmonary Hypertension Intervention:   Radiation: Thoracic computed tomography Sponsors:   Medical University of Graz;   Ludwig Boltzmann Institute Lung Vascular Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Pulmonary endarterectomy (PEA) is a curative surgical option for patients with chronic thromboembolic pulmonary hypertension (CTEPH), a disease resulting from chronic pulmonary thromboembolism. The role of sarcopenia (i.e. low skeletal muscle mass) has been shown to be associated with adverse outcomes in surgical populations, but its significance with PEA remains unknown. We sought to evaluate the association of sarcopenia with measures of CTEPH severity and post-operative hospital outcomes.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (57) Source Type: research
Pulmonary endarterectomy (PEA) is curative for suitable chronic thromboembolic pulmonary hypertension (CTEPH) patients. Careful anticoagulation prevents postoperative bleeding and thromboembolic recurrence. Heparinization is often guided by aPTT but it can be influenced by Factor VIII - a coagulation factor elevated in CTEPH. Anti-Xa-guided anticoagulation is less affected by other factors. We investigated the correlation between aPTT and Anti-Xa after PEA and the impact of coagulation factors.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (56) Source Type: research
Pulmonary artery sarcoma (PAS) is an exceedingly rare disease with historically poor survival. PAS is often mistaken for chronic thromboembolic pulmonary hypertension (CTEPH) owing to similarities in clinical presentation. Controversy exists regarding need to definitively differentiate PAS from CTEPH prior to surgical therapy. Furthermore lung resection would seem inferior palliation to tumor endarterectomy in a predominantly bilateral disease dominated by hemodynamic compromise.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (55) Source Type: research
More News: Hypertension | Pulmonary Hypertension | Research | Study